Fate Therapeutics Inc (FATE) Stock Price & Analysis
Fate Therapeutics Inc (FATE) fell 0.52% to USD 1.9 as of June 10, 2026 at 01:59 UTC, according to Nexqual real-time market data.
FATE last closed at USD 1.91; the session ranged USD 1.82–2.08 on volume of 1,881,024 shares. Market capitalization is $221.46M, with a 52-week range of USD 0.91–2.88 (NGM). Source: Nexqual, June 10, 2026 at 01:59 UTC.
Key Statistics (as of June 10, 2026 at 01:59 UTC)
| Price | USD 1.9 |
|---|---|
| Change | ▼ 0.52% (down) |
| Previous Close | USD 1.91 |
| Open | USD 1.93 |
| Day Range | USD 1.82 – 2.08 |
| 52-Week Range | USD 0.91 – 2.88 |
| Volume | 1,881,024 shares |
| Market Cap | $221.46M |
| Exchange | NGM |
Technical Analysis (FATE)
Nexqual's technical model rates FATE "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 01:59 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 47.17 (neutral) |
| vs SMA50 | Above (USD 1.75) |
| MACD | 0.09 (positive) |
Analyst Ratings (FATE)
Wall Street analysts rate FATE "Buy" based on 9 analysts, with a mean price target of USD 5.41 (range USD 2.2–8), per Nexqual as of June 10, 2026 at 01:59 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 5.41 |
| High Target | USD 8 |
| Low Target | USD 2.2 |
| Buy / Hold / Sell | 6 / 6 / 0 |
Earnings (FATE)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $943,860 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.26 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.27 vs est -0.28 ▲ beat |
| 2025-06-30 | USD -0.29 vs est -0.34 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Financials & Fundamentals (FATE)
| Total Revenue | $6.32M |
|---|---|
| Revenue Growth (YoY) | -20.30% |
| Gross Margin | +0.00% |
| Operating Margin | -2540.42% |
| Profit Margin | +0.00% |
| ROE | -55.50% |
| Debt / Equity | 42.73 |
| Current Ratio | 5.85 |
| Total Cash | $174.82M |
| Total Debt | $76.78M |
| Free Cash Flow | $-50.07M |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Financial Health Score (FATE)
Nexqual rates Fate Therapeutics Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:59 UTC.
| Growth | Critical — Revenue -51% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $175M cash vs $77M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$50M, burning cash |
| Efficiency | Critical — ROE -56%, ROA -25.3% |
Ownership (FATE)
| Insider Ownership | +1.17% |
|---|---|
| Institutional Ownership | +72.85% |
| Shares Outstanding | 116.56M |
| Float | 101.86M |
| Short % of Float | +10.40% |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Leadership (FATE)
Fate Therapeutics Inc is led by Bahram Valamehr (age 48), President, CEO & Director, per Nexqual as of June 10, 2026 at 01:59 UTC.
| President, CEO & Director | Bahram Valamehr (age 48) |
|---|---|
| CFO & Treasurer | Kamal Adawi M.S. (age 46) |
| Senior Vice President of Human Resources & Operations | Jessica Francis |
| Senior Vice President of Technical Operations & Quality | Tunde Babalola |
| Senior Director of Investor Relations & Business Development | Ryan Douglas |
Major Backers & Investors (FATE)
Notable institutional backers of Fate Therapeutics Inc include Redmile Group, LLC, Acadian Asset Management. LLC, Two Sigma Investments, LP, according to Nexqual as of June 10, 2026 at 01:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Redmile Group, LLC | 11.04% |
| Acadian Asset Management. LLC | 3.53% |
| Two Sigma Investments, LP | 2.97% |
| Johnson & Johnson | 2.9% |
| AQR Capital Management, LLC | 2.58% |
| Renaissance Technologies | 2.55% |
| Fidelity | 1.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.29% |
| BlackRock | 12.38% |
| Geode Capital | 2.22% |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
From Fate Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
- The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
- Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors.
- It has a collaboration and option agreement with Ono Pharmaceutical Co.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 3.88 | ▼ 8.27% |
| BEAM | Beam Therapeutics Inc. | USD 30.47 | ▲ 3.64% |
| ALLO | Allogene Therapeutics, Inc. | USD 1.82 | ▼ 3.19% |
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:59 UTC. This page is informational and not investment advice.